What has FDA done within the Agency to insure that nanoproducts are regulated in a coordinated fashion across all product types?
The Office of the Commissioner FDA has established a NanoTechnology Interest Group (NTIG) on which all FDA’s Centers and all FDA Offices that report directly to the Office of the Commissioner participate. Within the Centers of FDA, staffs have established multidisciplinary working groups. The goal of these FDA working groups is to share information about nanotechnology and to provide a level of coordination of review for the various product types. The working groups are charged with identifying and defining the regulatory challenges in the various review disciplines and to propose a path forward. The mission of the groups is then to propose solutions to overcome these challenges.
Related Questions
- To whom may covered entities make public health disclosures regarding a product regulated by the Food and Drug Administration (FDA) when more than one person is identified on the product label?
- What has FDA done within the Agency to insure that nanoproducts are regulated in a coordinated fashion across all product types?
- Which types of farms are regulated under current FDA laws?
